Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D2C7-IT and 2141-V11 for Recurrent Malignant Glioma
NCT04547777Phase 1Recruiting
- Sponsor
- Istari Oncology
- Start
- Jul 2021
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of 2141-V11 and D2C7-(scdsFv)-PE38KDEL in malignant glioma (2 arms), sponsored by Istari Oncology. Primary endpoints: Dose-Limiting Toxicity at 28 days, Unacceptable Toxicity from CPL Injections at 28 days and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
2141-V11D2C7-(scdsFv)-PE38KDEL
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT04547777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547777.